𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas

✍ Scribed by Carol S. Portlock; Dr. Saul A. Rosenberg

Publisher
John Wiley and Sons
Year
1976
Tongue
English
Weight
611 KB
Volume
37
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combination chemotherapy of diffuse hist
Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)
✍ Laurence Elias; Carol S. Portlock; Saul A. Rosenberg πŸ“‚ Article πŸ“… 1978 πŸ› John Wiley and Sons 🌐 English βš– 497 KB πŸ‘ 2 views

Twenty-three patients with diffuse histiocytic lymphoma who had not had prior chemotherapy were treated with CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone). Sixteen of these patients had previously been treated with radiation therapy. Nine of these 23 patients had a pathologically

Cyclophosphamide, vincristine, and predn
Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin's lymphomas
✍ Monfardini, Silvio ;Tancini, Gabriele ;Delena, Mario ;Villa, Eugenio ;Valagussa, πŸ“‚ Article πŸ“… 1977 πŸ› John Wiley and Sons 🌐 English βš– 464 KB

## Abstract In stage IV non‐Hodgkin's lymphomas, CVP (cyclophosphamide, vincristine, and prednisone) was randomly compared to ABP (adriamycin, bleomycin, and prednisone). Of 62 patients entered into the study, 57 (CVP 27, ABP 30) were considered evaluable for comparison. In patients with liver and/

Treatment of advanced non-Hodgkin's lymp
Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion
✍ Don V. Jackson Jr; Eugene H. Paschold; Charles L. Spurr; Hyman B. Muss; Fred Ric πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 532 KB

Twenty-five patients with a variety of histologic types of advanced non-Hodgkin's lymphoma refractory to previous chemotherapy were entered into a trial of vincristine infusion. Patients received 5-day courses of vincristine 0.25 mg/m2/day by continuous intravenous infusion after an initial 0.5 mg i